stay updated

Khondrion Secures up to €5 Million Innovation Credit from Dutch Government plus Additional Funding from Current Investors to Advance Phase 3 Clinical Trial in m.3243A>G Primary Mitochondrial Disease

Khondrion, a clinical-stage biopharmaceutical companypioneering therapies for primary mitochondrial disease (PMD), today announced it has beenawarded an Innovation Credit of up to €5 million from the Netherlands Enterprise Agency, agovernment agency that supports entrepreneurs...

UMDF and Khondrion Announce The Mito Fund’s Investment in Khondrion to Support Development of One of the Most Advanced Drug Candidates for Primary Mitochondrial Disease

The United Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Khondrion...

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...

Khondrion and Amsterdam UMC announce to initiate Phase 2 Clinical Trial of Sonlicromanol to Combat Long-Term Post-COVID Symptoms

Khondrion, a clinical-stage biopharmaceutical company specializing in mitochondrial disease therapies,...

Khondrion receives FDA clearance of IND application for pivotal Phase 3 clinical trial of sonlicromanol for the treatment of primary mitochondrial disease

52-week Phase 3 trial to investigate potential of novel, brain-penetrant redox-modulator with anti-inflammatory properties, in adult patients with...

Khondrion to Present Promising Advances in Mitochondrial Disease Therapy at Bio-Europe and Investival Showcase Events

NIJMEGEN, The Netherlands – October 29, 2024: Khondrion, a pioneering clinical-stage biopharmaceutical company focused on developing transformative...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

Can you explain a little about the work that International Mito Patients does? International Mito Patients (IMP) is a global network of 16 national...

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

A coffee with the Scientific Advisory Board: Prof. Dr. Michelangelo Mancuso

How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...

Patient Perspective: A conversation with Sam’s mother

When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...

A coffee with the Scientific Advisory Board: Prof. Dr. Marni Falk

How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...

Patient Perspective: A conversation with Paulien

When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...